Eve Holding Discloses Significant 2025 Losses and Executive Pay Amidst Capital Challenges
EVEX is trading near its 52-week low of $2.34 (14% above the low).
Summary
Eve Holding's definitive proxy statement reveals a substantial net loss of $224 million in 2025 and significant underperformance in Total Shareholder Return, despite a $230 million equity raise at $4.85 per share, highlighting ongoing capital challenges.
Key Events · Corporate Governance and Compliance · EVEX
-
Annual Meeting Scheduled
Eve Holding has scheduled its 2026 Annual Meeting of Stockholders for Thursday, May 21, 2026, to be held virtually. Key proposals include the election of two Class I directors, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent auditor.
-
Significant 2025 Net Loss and Underperforming TSR
The company reported a substantial net loss of $224,255,000 for the fiscal year ended December 31, 2025. Additionally, Eve Holding's Total Shareholder Return (TSR) of 55.42 significantly underperformed its peer group's TSR of 133.05 for the same period.
-
Details of $230M Equity Raise in 2025
The filing disclosed a registered direct offering on August 13, 2025, which raised approximately $230 million through the issuance of 47,422,680 shares at a purchase price of $4.85 per share. This capital raise occurred prior to the company's March 2026 10-K filing, which stated that current capital is insufficient.
-
Executive Compensation Payouts Amidst Losses
Despite the significant net losses and stock underperformance, executive officers received annual incentive payouts for achieving 99% of corporate goals in 2025. The CEO, Johann Bordais, received $345,646 in annual incentive compensation.
Analysis · EVEX · Manufacturing
This definitive proxy statement provides critical insights into Eve Holding's financial health and governance. The company reported a substantial net loss of $224 million for 2025 and its Total Shareholder Return significantly lagged its peer group. This performance context is crucial, especially given the prior disclosure in the March 2026 10-K that current capital is insufficient. The filing details a $230 million equity raise in August 2025 at $4.85 per share, a price considerably higher than the current stock price of $2.66, indicating a significant decline in market value since the capital infusion. Furthermore, executive officers received annual incentive payouts for achieving 99% of corporate goals, which may raise questions given the company's overall financial results. Investors should closely monitor the company's capital management strategies and future financing plans, as well as the outcomes of the upcoming annual meeting proposals.
At the time of this filing, EVEX was trading at $2.66 on NYSE in the Manufacturing sector, with a market capitalization of approximately $926.5M. The 52-week trading range was $2.34 to $7.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.